Story perspectives

Caregiver Support Programs Outshine Lecanemab in Cost-Effectiveness

2/5/2026

41 3

Summary

Story summary

A study published on February 5, 2026, in Alzheimer’s and Dementia: Behavior & Socioeconomics of Aging finds caregiver support programs may be more cost-effective than lecanemab, saving $300 billion versus $39.5 billion.
Lecanemab extends life by 0.17 years, while collaborative care keeps patients at home longer.
Experts say real-world data are needed to validate these findings and spur dementia-care reform as U.S. cases rise to more than 6 million.

1 of 1

Story summary

A study published on February 5, 2026, in Alzheimer’s and Dementia: Behavior & Socioeconomics of Aging finds caregiver support programs may be more cost-effective than lecanemab, saving $300 billion versus $39.5 billion.
Lecanemab extends life by 0.17 years, while collaborative care keeps patients at home longer.
Experts say real-world data are needed to validate these findings and spur dementia-care reform as U.S. cases rise to more than 6 million.